Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

Nasser K. Altorki(NewYork–Presbyterian Hospital), Timothy E. McGraw(NewYork–Presbyterian Hospital), Alain Borczuk(NewYork–Presbyterian Hospital), Ashish Saxena(NewYork–Presbyterian Hospital), Jeffrey L. Port(NewYork–Presbyterian Hospital), Brendon M. Stiles(NewYork–Presbyterian Hospital), Benjamin E. Lee(NewYork–Presbyterian Hospital), Nicholas J Sanfilippo(NewYork–Presbyterian Hospital), Ronald Scheff(NewYork–Presbyterian Hospital), Bradley B. Pua(NewYork–Presbyterian Hospital), James F. Gruden(NewYork–Presbyterian Hospital), Paul J. Christos(NewYork–Presbyterian Hospital), Cathy Spinelli(NewYork–Presbyterian Hospital), Joyce Gakuria(NewYork–Presbyterian Hospital), Manik Uppal(NewYork–Presbyterian Hospital), Bhavneet Binder(NewYork–Presbyterian Hospital), Olivier Elemento(NewYork–Presbyterian Hospital), Karla V. Ballman(NewYork–Presbyterian Hospital), Silvia C. Formenti(NewYork–Presbyterian Hospital)
The Lancet Oncology
May 18, 2021
Cited by 328

Abstract


Related Papers

No related papers found

Powered by citation graph analysis